drugset / Trial / NCT01845337

Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

NCT01845337

Phase 2 Completed 59 enrolled University of Edinburgh NHS Lothian · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Capecitabine is a chemotherapy drug used to treat many types of cancer including bowel and stomach cancer. Unfortunately a side effect of this drug is that it causes heart problems including heart attacks. An alternative drug, called teysuno is used extensively in other countries instead of capecitabine and appears to have less of a bad effect on the heart whilst still killing cancer cells. This study will investigate the effect of these two drugs on the heart and blood vessels and will be the first of its kind in humans.

Timeline

Start
2014-02-05
Primary completion
2020-03-18
Completion
2020-10-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 750 mg/m2 Oral
Comparator Capecitabine Small molecule 1000 mg/m2 Oral
Comparator Capecitabine Small molecule 1250 mg/m2 Oral
Comparator S-1 Small molecule 25 mg/m2 Oral
Comparator S-1 Small molecule 30 mg/m2 Oral
Comparator S-1 Small molecule 35 mg Oral
Comparator S-1 Small molecule 40 mg Oral
Comparator S-1 Small molecule 45 mg Oral
Comparator S-1 Small molecule 50 mg Oral
Comparator S-1 Small molecule 55 mg Oral